Latest news with #Imricor
The Australian
08-05-2025
- Business
- The Australian
Hungarian hospital debuts Imricor mapping system
The first procedure performed using Imricor's platform of devices in Hungary has taken place this week Procedure performed by Semmelweis, a highly regarded team known for advanced electrophysiology services and commitment to cutting-edge treatments Imaging and mapping system designed to enable higher success rates with faster, safer treatments compared to conventional methods. Special Report: In a new step toward European expansion, the first atrial flutter ablations procedure guided by real-time MRI using Imricor's platform of devices in Hungary has taken place at the Semmelweis University's Heart and Vascular Centre in Budapest. Imricor (ASX:IMR) has welcomed the further deployment of its technology, which is designed to improve medical intervention procedures by using real-time magnetic resonance imaging (MRI) guidance, rather than traditional x-ray fluoroscopy guidance. The company is confident its tech is safer and more cost effective, offering higher success rates due to the increased detail offered, particularly in soft tissues and organs, without the use of ionizing radiation. Imricor chair and CEO Steve Wedan said he was thrilled to have another world-class medical institution begin real-time MRI-guided ablation procedures, and excited to expand IMR's installed base into Hungary. 'With our European sales team nearly fully staffed, we are looking forward to continued expansion and growth across Europe, including adding additional sites to our VISABL-VT trial, where we expect the power of real-time periprocedural magnetic resonance imaging to improve patient outcomes and lower procedure times, all in an environment that is 100% free of dangerous ionising radiation,' Wedan said. 'That's our mission.' What are cardiac catheter ablation procedures? Cardiac catheter ablation procedures are a type of minimally invasive procedure used to treat abnormal heart rhythms. It involves guiding thin, flexible catheters (tubes) through blood vessels to the heart and using heat or cold to create small scars that disrupt faulty electrical signals which cause irregular heartbeat. The procedure is typically guided by x-ray imaging, but x-rays are better suited for visualising bone structures and hard tissues. The Vision-MR Ablation Catheter is Imricor's primary offering, designed to work under real-time MRI guidance with the goal of offering better soft tissue imaging without exposure to ionising radiation through x-ray imaging. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
News.com.au
27-04-2025
- Business
- News.com.au
ASX medtechs at the forefront of precision, safety and efficiency in healthcare
Certain ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency in healthcare For example, Imricor is pioneering cardiac ablations using MRI instead of traditional x-ray fluoroscopy to treat arrhythmias faster and safer And Singular Health's 3Dicom technology is helping reduce duplicate scans, cutting costs and minimising risks of over-imaging As the medical world strives to diagnose disease earlier for better outcomes, treat conditions more precisely and increase efficiency while reducing healthcare costs, ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency. From early detection of coronary disease, or reducing exposure to radiation for patients and medical staff by replacing x-ray with MRI in cardiac ablation procedures, these medtechs are improving outcomes while delivering greater value through advanced clinical workflows and cost-efficient care. Morgans healthcare analyst Iain Wilkie told Stockhead that the "golden child" of ASX medtechs ProMedicus (ASX:PME) was a prime example of the innovation and AI-driven advancements that make local companies in the sector so attractive. Pro Medicus is a global provider of radiology IT software for hospitals, imaging centres and healthcare networks with its flagship Visage platform delivering ultra-fast imaging and advanced visualisation tools, enabling radiologists to interpret scans remotely – even on mobile devices. "I see Pro Medicus as the best company on the ASX and they have barely put a foot wrong," Wilkie said. "On a valuation basis it's still expensive, but that's been the case for a number of years already and if you're growing 30% year-on-year it doesn't take long to get to a normal valuation. "Key here though is picking it up on weakness, which, coming down from almost $300 to now around $200 is a reasonable entry point and what we have been waiting for a while. 'Like the baby brother' of Pro Medicus Described by Wilkie as "like the baby brother" of Pro Medicus, Mach7 Technologies (ASX:M7T) aims to improve the efficiency and workflow for radiologists, other clinical staff and healthcare organisations with its medical imaging software solutions, Mach7's enterprise imaging solution comprises enterprise data management, enterprise diagnostic viewing and departmental workflow applications. The company's enterprise data management solution consists of a vendor neutral archive (VNA) and data administration tools to enable for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the cloud. Its eUnity enterprise diagnostic viewing technology is an image-viewing solution that makes images accessible on any workstation. Mach7 recently announced the head of formerly ASX-listed Volpara Health Technologies, a leader in medical software for breast cancer screening, had been appointed managing director and CEO. Volpara was acquired by South Korean-based provider of AI-powered solutions for cancer diagnostics and therapeutics Lunit in May 2024 for $292 million. Imricor replaces x-ray with MRI for cardiac ablations Imricor Medical Systems (ASX:IMR) is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively. Cardiac ablations, a procedure that targets and destroys heart cells causing arrhythmias (irregular heartbeats), currently use x-ray fluoroscopy. While effective in visualising hard structures such as ribs, x-ray struggles with soft tissue like the heart, leading to long-term lower success rates, often below 50%, and requiring repeat procedures. Imricor said its MRI-compatible devices for cardiac ablations offer superior ability to visualise the heart and blood vessels, leading to better outcomes, while also reducing exposure of patients and medical staff to radiation. The company is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US Food and Drug Administration (FDA) approval of its products, which it hopes to achieve in 2025. In Europe, where the company has already received regulatory approval for atrial flutter, Imricor recently started its pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT) and has achieved several world-firsts. "Even though it's the same price as existing standard of care, the theory is MRI-guided ablations can improve procedure times so doctors can treat more people per day, with comparable or better patient outcomes (more accurate and durable therapy), and with no radiation," Wilkie said. Singular Health is reducing need for duplicate imaging Singular Health Group Ltd (ASX:SHG) is improving efficiency in health imaging, reducing duplicate scans to save costs but also reduce risks of over-imaging with its 3Dicom technology. A study published this month looked at how many future cancers could result from radiation exposure from annual computed tomography (CT) examinations in the US. The findings suggested that low levels of ionising radiation from CT scans could account for 5% of all new cancer diagnoses in the US. "Every unnecessary CT scan avoided is one less dose of radiation, one less cancer risk, one more patient protected," Singular Health co-founder and CEO Denning Chong said. "Singular Health is building the tools to make that possible – integrating imaging data, empowering clinicians with 3D visualisation, and cutting out waste in a system that desperately needs it." FDA-cleared 3Dicom translates and converts MRIs, CT and PET scans into 3D or virtual reality and extended reality (VR-XR) models. But where Singular Health sees real commercial opportunity is in the viewing, sending, storing and AI analysis of the images for patients and hospitals, managed service organisations and health plans. Singular Health's 3Dicom solution provides the infrastructure to facilitate the use of AI models available in the marketplace on images in transit, to provide stakeholders with more accurate analysis, resulting in reducing misdiagnosis and increasing rates of pre diagnosis. Chong said that in the US in particular, the need to extract better value from images and reduce duplicate imaging costs was critical. The 3Dicom Gateway solution gives each stakeholder standardised viewing, image access, and AI analysis during transit — capabilities they previously lacked. "We are absolutely committed to provide our 3Dicom Gateway solution to not only reduce the unnecessary cost and burden of duplicate imaging, but also to reduce risks to patients such as cancer risks by reducing the need for an unnecessary scan," Chong said. "Even one patient protected is worth the effort." Imagion transforming cancer diagnosis Through its MagSense platform, Imagion Biosystems (ASX:IBX) is aiming to transform cancer diagnosis by introducing molecular imaging to widely available magnetic resonance imaging (MRI). Executive chairman Robert Proulx said MagSense had the potential to improve on current techniques for cancer diagnosis such as x-rays, conventional MRI, CT, ultrasounds and positron emission tomography (PET) by providing a more specific and personalised approach. The MagSense imaging platform involves the use of iron oxide nanoparticles labelled with cancer-specific targeting antibodies, which can then be imaged with MRI. The company is pursuing initial indication in HER2+ breast cancer staging – a form of cancer known to be highly aggressive – with pipeline candidates for prostate and ovarian cancers. "Accuracy or specificity is the big play here and today we have multiple ways of imaging the body and they are all able to find anatomical anomalies," he said. "But they can't tell if these anomalies are a malignant tumour or a benign mass and that is the problem we are trying to solve with our MagSense imaging agent." Proulx said the MagSense particles add specificity so when it shows up on an MRI you know it's there because of the targeting molecules binding to a certain type of tumour. "You have the normal aspect of an MRI with anatomical imaging showing something is unusual in size and shape but also added benefit of the presence of our particle actually showing there are cancer cells because they are bound by the targeting molecule," he said. Imagion recently announced its plans to take the MagSense HER2 breast-cancer imaging agent into a phase II study to be proposed to the FDA in an Investigational New Drug application. Atrya using AI to diagnose coronary artery disease Artrya (ASX:AYA) is using the power of AI for "fast, accurate and non-invasive assessment of coronary artery disease to drive precision medicine, reducing time and costs, and save lives". In March, Artyra received FDA 510(k) clearance for its flagship platform, Salix Coronary Anatomy (SCA), which analyses coronary CT angiography (CCTA) scans and provides the clinician with accurate, real-time information on the existence and extent of high-risk plaque in the arteries – the main cause of death. CEO Mathew Regan said SCA was the first point-of-care approach in 50 years for assessing coronary artery disease, the world's leading cause of death. "For decades, heart disease has been treated reactively, waiting for symptoms to appear before taking action," he said in an ASX announcement. "With FDA clearance of Salix Coronary Anatomy, hospitals and clinics can now move beyond traditional diagnostics to a truly proactive approach." With someone in the US suffering a heart attack every 40 seconds, the company forecasts the US market opportunity to be significant, based on 4.4 million CCTA scans annually, and projected to grow at 6.2% per year. Following FDA clearance of the SCA platform Artrya has two further upcoming product submissions including for Salix Coronary Plaque and then Salix Coronary Flow. The company anticipates FDA clearance for both products by the end of 2025, unlocking access to two distinct reimbursement codes for detailed plaque and blood flow analysis in the US healthcare market. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Imricor, Singular Health and Imagion Biosystems are Stockhead advertisers, the companies did not sponsor this article.
Mercury
27-04-2025
- Business
- Mercury
ASX medtechs transforming healthcare
Certain ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency in healthcare For example, Imricor is pioneering cardiac ablations using MRI instead of traditional x-ray fluoroscopy to treat arrhythmias faster and safer And Singular Health's 3Dicom technology is helping reduce duplicate scans, cutting costs and minimising risks of over-imaging As the medical world strives to diagnose disease earlier for better outcomes, treat conditions more precisely and increase efficiency while reducing healthcare costs, ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency. From early detection of coronary disease, or reducing exposure to radiation for patients and medical staff by replacing x-ray with MRI in cardiac ablation procedures, these medtechs are improving outcomes while delivering greater value through advanced clinical workflows and cost-efficient care. Morgans healthcare analyst Iain Wilkie told Stockhead that the "golden child" of ASX medtechs ProMedicus (ASX:PME) was a prime example of the innovation and AI-driven advancements that make local companies in the sector so attractive. Pro Medicus is a global provider of radiology IT software for hospitals, imaging centres and healthcare networks with its flagship Visage platform delivering ultra-fast imaging and advanced visualisation tools, enabling radiologists to interpret scans remotely – even on mobile devices. "I see Pro Medicus as the best company on the ASX and they have barely put a foot wrong," Wilkie said. "On a valuation basis it's still expensive, but that's been the case for a number of years already and if you're growing 30% year-on-year it doesn't take long to get to a normal valuation. "Key here though is picking it up on weakness, which, coming down from almost $300 to now around $200 is a reasonable entry point and what we have been waiting for a while. 'Like the baby brother' of Pro Medicus Described by Wilkie as "like the baby brother" of Pro Medicus, Mach7 Technologies (ASX:M7T) aims to improve the efficiency and workflow for radiologists, other clinical staff and healthcare organisations with its medical imaging software solutions, Mach7's enterprise imaging solution comprises enterprise data management, enterprise diagnostic viewing and departmental workflow applications. The company's enterprise data management solution consists of a vendor neutral archive (VNA) and data administration tools to enable for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the cloud. Its eUnity enterprise diagnostic viewing technology is an image-viewing solution that makes images accessible on any workstation. Mach7 recently announced the head of formerly ASX-listed Volpara Health Technologies, a leader in medical software for breast cancer screening, had been appointed managing director and CEO. Volpara was acquired by South Korean-based provider of AI-powered solutions for cancer diagnostics and therapeutics Lunit in May 2024 for $292 million. Imricor replaces x-ray with MRI for cardiac ablations Imricor Medical Systems (ASX:IMR) is pioneering real-time interventional cardiac MRI (iCMR) ablations – using MRI instead of traditional x-ray fluoroscopy to treat cardiac arrhythmias faster, safer and more effectively. Cardiac ablations, a procedure that targets and destroys heart cells causing arrhythmias (irregular heartbeats), currently use x-ray fluoroscopy. While effective in visualising hard structures such as ribs, x-ray struggles with soft tissue like the heart, leading to long-term lower success rates, often below 50%, and requiring repeat procedures. Imricor said its MRI-compatible devices for cardiac ablations offer superior ability to visualise the heart and blood vessels, leading to better outcomes, while also reducing exposure of patients and medical staff to radiation. The company is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US Food and Drug Administration (FDA) approval of its products, which it hopes to achieve in 2025. In Europe, where the company has already received regulatory approval for atrial flutter, Imricor recently started its pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT) and has achieved several world-firsts. "Even though it's the same price as existing standard of care, the theory is MRI-guided ablations can improve procedure times so doctors can treat more people per day, with comparable or better patient outcomes (more accurate and durable therapy), and with no radiation," Wilkie said. Singular Health is reducing need for duplicate imaging Singular Health Group Ltd (ASX:SHG) is improving efficiency in health imaging, reducing duplicate scans to save costs but also reduce risks of over-imaging with its 3Dicom technology. A study published this month looked at how many future cancers could result from radiation exposure from annual computed tomography (CT) examinations in the US. The findings suggested that low levels of ionising radiation from CT scans could account for 5% of all new cancer diagnoses in the US. "Every unnecessary CT scan avoided is one less dose of radiation, one less cancer risk, one more patient protected," Singular Health co-founder and CEO Denning Chong said. "Singular Health is building the tools to make that possible – integrating imaging data, empowering clinicians with 3D visualisation, and cutting out waste in a system that desperately needs it." FDA-cleared 3Dicom translates and converts MRIs, CT and PET scans into 3D or virtual reality and extended reality (VR-XR) models. But where Singular Health sees real commercial opportunity is in the viewing, sending, storing and AI analysis of the images for patients and hospitals, managed service organisations and health plans. Singular Health's 3Dicom solution provides the infrastructure to facilitate the use of AI models available in the marketplace on images in transit, to provide stakeholders with more accurate analysis, resulting in reducing misdiagnosis and increasing rates of pre diagnosis. Chong said that in the US in particular, the need to extract better value from images and reduce duplicate imaging costs was critical. The 3Dicom Gateway solution gives each stakeholder standardised viewing, image access, and AI analysis during transit — capabilities they previously lacked. "We are absolutely committed to provide our 3Dicom Gateway solution to not only reduce the unnecessary cost and burden of duplicate imaging, but also to reduce risks to patients such as cancer risks by reducing the need for an unnecessary scan," Chong said. "Even one patient protected is worth the effort." Imagion transforming cancer diagnosis Through its MagSense platform, Imagion Biosystems (ASX:IBX) is aiming to transform cancer diagnosis by introducing molecular imaging to widely available magnetic resonance imaging (MRI). Executive chairman Robert Proulx said MagSense had the potential to improve on current techniques for cancer diagnosis such as x-rays, conventional MRI, CT, ultrasounds and positron emission tomography (PET) by providing a more specific and personalised approach. The MagSense imaging platform involves the use of iron oxide nanoparticles labelled with cancer-specific targeting antibodies, which can then be imaged with MRI. The company is pursuing initial indication in HER2+ breast cancer staging – a form of cancer known to be highly aggressive – with pipeline candidates for prostate and ovarian cancers. "Accuracy or specificity is the big play here and today we have multiple ways of imaging the body and they are all able to find anatomical anomalies," he said. "But they can't tell if these anomalies are a malignant tumour or a benign mass and that is the problem we are trying to solve with our MagSense imaging agent." Proulx said the MagSense particles add specificity so when it shows up on an MRI you know it's there because of the targeting molecules binding to a certain type of tumour. "You have the normal aspect of an MRI with anatomical imaging showing something is unusual in size and shape but also added benefit of the presence of our particle actually showing there are cancer cells because they are bound by the targeting molecule," he said. Imagion recently announced its plans to take the MagSense HER2 breast-cancer imaging agent into a phase II study to be proposed to the FDA in an Investigational New Drug application. Listen to Health Kick Podcast: Imagion's cancer imaging alternative Atrya using AI to diagnose coronary artery disease Artrya (ASX:AYA) is using the power of AI for "fast, accurate and non-invasive assessment of coronary artery disease to drive precision medicine, reducing time and costs, and save lives". In March, Artyra received FDA 510(k) clearance for its flagship platform, Salix Coronary Anatomy (SCA), which analyses coronary CT angiography (CCTA) scans and provides the clinician with accurate, real-time information on the existence and extent of high-risk plaque in the arteries – the main cause of death. CEO Mathew Regan said SCA was the first point-of-care approach in 50 years for assessing coronary artery disease, the world's leading cause of death. "For decades, heart disease has been treated reactively, waiting for symptoms to appear before taking action," he said in an ASX announcement. "With FDA clearance of Salix Coronary Anatomy, hospitals and clinics can now move beyond traditional diagnostics to a truly proactive approach." With someone in the US suffering a heart attack every 40 seconds, the company forecasts the US market opportunity to be significant, based on 4.4 million CCTA scans annually, and projected to grow at 6.2% per year. Following FDA clearance of the SCA platform Artrya has two further upcoming product submissions including for Salix Coronary Plaque and then Salix Coronary Flow. The company anticipates FDA clearance for both products by the end of 2025, unlocking access to two distinct reimbursement codes for detailed plaque and blood flow analysis in the US healthcare market. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Imricor, Singular Health and Imagion Biosystems are Stockhead advertisers, the companies did not sponsor this article. Disclosure: The journalist held shares in Mach7 Technologies at the time of writing this article. Originally published as ASX medtechs at the forefront of precision, safety and efficiency in healthcare
Mercury
24-04-2025
- Business
- Mercury
ASX health stocks deliver March quarter progress
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. ASX quarterly season is upon us again, with listed companies opening a window to their performance and key activities over the three months to March 31. It's a key time for investors to zero in on the finer details of ASX-listed firms and get a sense of what is on the horizon. Here, we wrap up report highlights from four standout stocks in the ASX health sector. Imricor submitted second module for premarket approval of its products to US FDA during quarter Second -generation Vision-MR Ablation Catheter receives CE mark certification under new European Medical Device Regulation After quarter end Imricor started its VISABL-VT pivotal trial at Amsterdam University Medical Centre achieving world-firsts Imricor, which has developed the world's only MRI-compatible devices for cardiac ablations, made several regulatory achievements during Q1 CY25 including submitting the second module for premarket approval of its products to the US Food and Drug Administration (FDA). Among other highlights of a milestone quarter for the company, IMR received CE Mark approval for its second generation Vision-MR Ablation Catheter under the new more stringent European Medical Device Regulation (MDR). Subsequent to quarter end, Imricor started its VISABL-VT pivotal trial at Amsterdam University Medical Centre, achieving the first-in-human ventricular ablation guided by real-time iCMR. On the commercial front, the company is rebuilding its European sales team with the first capital sales managers in the US hired in preparation for commercial launch. Imricor B.V. was established in the Netherlands with the company opening an office in Amsterdam. The company also attended the Gulf Arrhythmia Congress in Dubai and EHRA Congress in Vienna. Imricor finished Q1 FY25 with a strong cash position following a $70 million capital raising, closing with a cash balance of US$53.9m (~A$85.5m). Race's lead site of Southside Cancer Centre in NSW for phase I trial of RC220 in combination with doxorubicin receives ethics and regulatory approval Screening of patients underway at centre with treatment of first patient scheduled for this quarter Human ethics approval also received to start trial at Gosford and Wyong hospitals in New South Wales Race made significant progress in Q3 FY25 towards first patient treatment in its phase I trial of its cardioprotective therapeutic RC220 in combination with doxorubicin in patients with advanced solid tumours. Ethics and all regulatory approvals were received for the lead site of Southside Cancer Care Centre, in Miranda NSW enabling recruitment of patients. Screening of patients has begun and the treatment of the first patient with RC220 is expected in the current quarter. Human ethics approval was also received to begin the trial at the Gosford and Wyong Hospitals, in the Central Coast Local Health District of NSW. Race said ethics approval allowed both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. Final approvals are expected during April. As of March 31, 2025, Race held cash and cash equivalents of $17.12m. The company said more than 70% of spending during Q3 ($1.67m) was directed toward R&D and drug manufacturing activities. "Like everyone at Race, I am looking forward to seeing the first patient treated with RC220 in this quarter and converting RC220's potential into meaningful outcomes for cancer patients and our shareholders," CEO Dr Daniel Tillett said. Clever Culture Systems targeting profitability in FY25 and building a substantial sales pipeline to underpin growth in FY26 Sales pipeline for APAS Independence Instruments exceeds 40 qualified customer opportunities in pharmaceutical market Company's APAS Independence instruments remain the only US FDA-cleared AI technology for automated culture plate reading Clever Culture CEO and managing director Brent Barnes said just over 12 months since its launched its APAS (automated plate assessment system) Independence instruments (culture plate readers) in the pharmaceutical market, the response had been "overwhelmingly positive" as it targets FY25 profitability. The company has 13 instruments sold or pre-ordered to date, representing ~$6m in revenue. That will set a base for future recurring revenue from licence fees and maintenance support. In a trading update, Clever Culture said it was building a substantial sales pipeline to underpin FY26 growth with 40 active and qualified customer opportunities within the pharmaceutical industry, representing ~$75m in potential upfront sales revenue and $15m per annum recurring revenue. The company's APAS Independence instruments remain the only US FDA-cleared AI technology for automated culture plate reading. A second purchase order has been received from an additional Bristol Myers Squibb (BMS) facility, which is expected to form a case study for the potential roll out to other BMS sites. Another big-pharma was completing an expanded 6000 plate evaluation, clearing the way for procurement discussions direct with their manufacturing sites. The company said active engagement with potential customers had accelerated noticeably since it announced the planned launch of a second APAS analysis module for analysis of the smaller contact plates (55mm) in October 2024. Combined with the existing APAS analysis module for the settle plates (90mm), the APAS Independence will be able to analyse the two plate types that make up the vast majority of tests used by pharmaceutical manufacturers in environmental monitoring. "Our strategy has been to target global pharmaceutical manufacturers that operate multiple sites globally and represent multi-instrument sales opportunities," Barnes said. Over the past three months the APAS Independence Instruments had been showcased at several leading international conferences. EZZ launches two new products during Q3 FY25 and upgrades formulas and packaging of three of its top sellers Company progresses strategic entry to US market with planned entry targeted for H2 FY25 EZZ serves up an ace with its inaugural sponsorship of the Australian Open in January covering China and Southeast Asia Genomic life sciences company EZZ successfully launched two new products during Q3 FY25, which it said leveraged consumer insights to meet evolving market trends and enhance the company's competitive positioning. EZZ also upgraded the formulas and packaging of three of its top selling products and strengthened domestic distribution by securing listings in ~70 new retail pharmacy distribution points in Australia. The company also progressed its strategic entry into the US market through comprehensive market research, collaboration with key local partners, and the development of a phased market entry plan targeted for H2 FY25. One of the highlights of Q3 was EZZ's elevated brand awareness, with the company serving an ace in its inaugural sponsorship of the Australian Open in January covering China and Southeast Asia, including influencer-hosted livestreams and content creation. EZZ said the campaign, it biggest marketing venture to date, delivered strong visibility across China and Southeast Asia, supported by prominent on-court branding. Meanwhile, the company continued to strengthen its brand positioning and consumer engagement on leading e-commerce platforms and initiated new customer loyalty initiatives to drive long-term growth in China. The company also reinforced industry presence and global networking through participation in the Cosmoprof Worldwide Bologna and the Australian Pharmacy Professional (APP) Conference nd Trade Exhibition, both held in March. Receipts from customers totalled $14.6m during Q3, which EZZ said reflected lower seasonal turnover in January and February compared to PCP, partly due to reduced digital advertising spend. The company said strong operating performance resulted in $1.5m of positive cash inflow. Cash reserves reached a record $21.1 million as at March 31 2025, with EZZ remaining debt-free, excluding lease liabilities. At Stockhead, we tell it like it is. While Imricor Medical Systems, Race Oncology, Clever Culture Systems and EZZ Life Science are Stockhead advertisers, they did not sponsor this article. Originally published as ASX Quarterly Health Wrap: Imricor starts CY25 strong, Clever Culture eyes FY25 profit
Web Release
24-04-2025
- Entertainment
- Web Release
An Omakase Experience with Executive Chef Sin Keun Choi at Ronin, FIVE LUXE
Entertainment Web Release Selection By Editor_wr On Apr 24, 2025 Surrender to an Omakase experience like no other where culinary virtuoso and celebrity Executive Chef, Sin Keun Choi orchestrates an intimate, multi-course journey designed to seduce the senses at Ronin, FIVE LUXE. Prepare to be seduced by an unforgettable Omakase experience at Ronin, FIVE LUXE's irezumi-inspired restaurant. Featuring exquisite signature dishes and daily specials, each experience is tailour-made by Executive Chef Sin Keun Choi, drawing from the day's freshest, premium Japanese ingredients and the guests' unique preferences. From the irresistible crunch of truffle-infused rolls to the decadent allure of foie gras cannelés, the captivating Ronin Tei-Shoku and an exclusive array of freshly rolled sushi, each Omakase dinner is a culinary revelation. With a deft hand and a discerning eye, Executive Chef Sin Keun Choi transforms seasonality and spontaneity into a multi-course journey that's as sensual as it is exclusive. Location: Ronin, FIVE LUXE, JBR When: Available daily from 7PM onwards Pricing: AED599 per person Follow us: Instagram | Website Book Now: Call: +971 4 455 9989 Email: [email protected] **Advance bookings are recommended. An Omakase Experience with Executive Chef Sin Keun Choi at RoninFIVE LUXE Prev Post Imricor Commences VISABL-VT Trial Comments are closed.
